A study to investigate the effect of oral ticagrelor on the pharmacokinetics of oral rosuvastatin when given in healthy participants

Study identifier:D3560C00817

ClinicalTrials.gov identifier:NCT06554821

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

An open-label, randomised, parallel-group, fixed-sequence study to assess the effect of oral ticagrelor on the pharmacokinetics of oral rosuvastatin in healthy participants

Medical condition

Healthy Participants

Phase

Phase 1

Healthy volunteers

Yes

Study drug

Rosuvastatin, Ticagrelor

Sex

All

Estimated Enrollment

28

Study type

Interventional

Age

18 Years - 55 Years

Date

Study Start Date: 05 Aug 2024
Estimated Primary Completion Date: 01 Oct 2024
Estimated Study Completion Date: 01 Oct 2024

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Other

Verification:

Verified 01 Sept 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

PAREXEL

Inclusion and exclusion criteria